News Releases

COTA, Inc. to Showcase the Importance of Real-World Evidence at HIMSS19
Company founder to present on the benefits for oncology care

NEW YORK, Feb. 4, 2019 /PRNewswire/ -- COTA, Inc., a leading precision medicine technology company that uses real-world evidence to transform cancer care, today announced the company will be exhibiting at the 2019 HIMSS Global Conference & Exhibition, from February 11–15 in Orlando. The company will be in booth #978 demonstrating the role real-world evidence (RWE) plays in the provider, payer, and life sciences spaces, and how it can deliver clinically relevant insights to improve overall cancer care while reducing costs. 

Cota Logo.

Using the COTA Nodal Address® (CNA) system – a unique digital classification methodology that stratifies patients into clinically precise cohorts – providers are able to analyze and visualize real-world, patient-level clinical and cost data. This organized and de-identified patient data now has the ability to provide deep and accurate real-world clinical evidence in real-time, allowing for the ability to make a difference at the point of care. Leveraging COTA's CNA system, the COTA Real-World Analytics (RWA) technology allows providers to identify treatment approaches that optimize the quality of care and extend best practices across their clinical enterprise, while also driving practice transformation.

On Monday, February 11, COTA founder Andrew Pecora, MD, who serves as the President, Physician Services Division, Chief Innovation Officer at Hackensack Meridian Health, will be presenting in two sessions around the benefits of RWE:

  • Cognitive Computing and Real-World Data in a Breast Cancer Clinic: Dr. Pecora and Stanley Waintraub Chief, Division of Breast Oncology, John Theurer Cancer Center at Hackensack University, will touch upon the benefits of RWE for clinical decision making. 11:20a.m. - 11:40a.m. ET in Rosen Centre Rosen Centre Jr. Ballroom F.
  • Panel Discussion: Healthcare's Innovation Challenge: Dr. Pecora will take part in a panel discussion to discuss what's necessary to successfully deploy machine learning & artificial intelligence in healthcare. 12:00p.m.-12:30p.m. in the Rosen Centre Rosen Centre Jr. Ballroom F.

"A growing number of stakeholders – including providers and payers – are realizing the importance of precision medicine and real-world evidence when it comes to transforming cancer care," said Mike Doyle, CEO of COTA. "We're excited to be attending HIMSS19 this year to discuss how the application of RWE can enable precision medicine at scale in oncology care. This ultimately supports better care decisions through the application of the right data – and each one of those decisions has the opportunity to improve the overall lives of cancer patients."

To learn more about COTA's products and the benefits of RWE, stop by booth #978 (near the Personalized Health Experience space) or visit If you would like to schedule a meet up with a COTA employee during the conference, email us at

About COTA, Inc.
Founded by oncologists and data scientists, COTA, Inc. builds solutions that analyze real-world evidence and deliver clinically relevant insights to improve cancer care. The Company partners with providers, payers, and life science companies involved in diagnosing and treating complex diseases to optimize the outcomes of individual patients and lower overall healthcare costs. Through its EMR-agnostic patented COTA Nodal Address® (CNA) system, a unique digital classification methodology that stratifies patients into distinct cohorts, COTA is enabling precision medicine at scale. To learn more about COTA and how to make better healthcare decisions with the right data, visit

For more information, please contact:

Jaimee Ryan

Melissa Brouillette 

COTA, Inc.

Next Step Communications